InsidersTradesSigma
Follow the NEUROCRINE BIOSCIENCES, INC. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 9 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: INGRID DELAET. Every trade is openly available.
Analysts rate NEUROCRINE BIOSCIENCES, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Neurocrine Biosciences, Inc. 是一家生物制药公司，专注于开发神经和精神疾病的治疗方法。它在纳斯达克上市，股票代码为 NBIX。